Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
E. Zah, E. Nam, V. Bhuvan, V. T. T. Tran, B. Y. Ji, S. B. Gosliner, X. Wang, C. E. Brown, Y. Y. Chen
This study develops BCMA/CS1 bispecific CAR-T cells that effectively target heterogeneous multiple myeloma, showing improved activity and durable tumor-free survival compared to single-target CAR-T cells.
bioRxiv · Mar 12, 2020Bioengineering